Back to Search Start Over

Efficacy and Insights from an Extensive Series of Cytoreductive Surgery for Peritoneal Neoplasms: A High-Volume Single-Center Experience.

Authors :
Aulicino, Matteo
Santullo, Francesco
D'Annibale, Giorgio
Abatini, Carlo
Attalla El Halabieh, Miriam
Orsini, Cecilia
Barberis, Lorenzo
D'Agostino, Luca
Tersigni, Ilaria
Pacelli, Fiammetta
Lodoli, Claudio
Di Giorgio, Andrea
Ferracci, Federica
Pacelli, Fabio
Source :
Cancers; Dec2024, Vol. 16 Issue 24, p4229, 17p
Publication Year :
2024

Abstract

Simple Summary: Cytoreductive surgery and intraperitoneal chemotherapy (HIPEC or PIPAC) are effective treatment options for peritoneal carcinomatosis from various primary diseases. An accurate pre-operative assessment and multidisciplinary evaluations are crucial in identifying the most suitable treatment approaches. This study aims to present a case series from a high-volume center to contribute valuable data to the existing literature on peritoneal carcinomatosis managing. Background: Advances in cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC) have improved outcomes for selected patients with peritoneal surface malignancies (PSMs). Methods: This retrospective study analyzed 743 PSM patients treated at Fondazione Policlinico Universitario Agostino Gemelli from January 2016 to February 2024. The primary aim was to assess median overall survival (mOS), median disease-free survival (mDFS), and median progression-free survival (mPFS) stratified by tumor origin. Secondary outcomes examined the role of diagnostic laparoscopy in the management of PSMs and intra- and postoperative complications' rates. Results: A total of 1113 procedures were performed: 389 CRS, 370 PIPAC, and 354 diagnostic laparoscopies. Colorectal cancer was the predominant indication for CRS (52.4%), with a mOS of 52 months and mDFS of 22 months. Patients affected by gastric cancer undergoing CRS had a mOS of 18 months and a mDFS of 13 months, while PIPAC yielded a mOS of 9 months and a mPFS of 4 months. Among patients with pseudomyxoma peritonei undergoing CRS, the 5-year DFS rate was 64.1%, and OS rate was 89%. Patients affected by mesothelioma and treated with CRS exhibited a median OS of 43 months and a DFS of 26 months. Pancreatic and hepatobiliary cancers were treated with PIPAC, with a respective mOS of 12 and 8 months. Postoperative complications occurred in 12.6% of CRS, 3.2% of PIPAC, and 1.7% of diagnostic laparoscopies. High peritoneal cancer index (PCI), gastric resection, and blood loss over 500 mL were identified as risk factors for major complications in a multivariate analysis. Conclusions: Developing a highly experienced multidisciplinary team is crucial for delivering tailored treatment strategies which aim to achieve optimal oncological outcomes while preserving patients' quality of life. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20726694
Volume :
16
Issue :
24
Database :
Complementary Index
Journal :
Cancers
Publication Type :
Academic Journal
Accession number :
181915607
Full Text :
https://doi.org/10.3390/cancers16244229